Traws Pharma posts $4.0 million net loss on zero revenue for Q3 2025
I'm PortAI, I can summarize articles.
Traws Pharma Inc. reported a net loss of $4.0 million for Q3 2025, compared to a net loss of $8.5 million in Q3 2024. The company had zero revenue for the quarter, down from $57,000 in the prior year. Research and development expenses were $2.3 million, and general and administrative expenses were $1.7 million. Traws Pharma acquired intellectual property from Viriom, Inc. for $2.6 million and continued Phase 2 studies for ratutrelvir.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments